Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 381 to 390 of 981 total matches.
Drugs for Epilepsy
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
and Pregnancy – The potential risk to offspring from in utero exposure to ASMs is generally considered ...
When used for the appropriate seizure type,
antiseizure medications (ASMs) are roughly
equivalent in efficacy. In addition to the seizure type,
the choice of drug is usually based on factors such
as ease of use, spectrum of activity, adverse effects,
interactions with other drugs, presence of comorbid
conditions, suitability for elderly persons and those
with childbearing potential, and cost. Treatment
should begin with a single drug, increasing the
dosage gradually until seizures are controlled or
adverse effects become unacceptable. If seizures
persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8 doi:10.58347/tml.2024.1708a | Show Introduction Hide Introduction
Pneumococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Sep 10, 1999 (Issue 1061)
treatment. It can be given at the
same time as influenza vaccine, at a different site. Use during pregnancy ...
Increased resistance of pneumococci to antimicrobial drugs may encourage more extensive use of pneumococcal polysaccharide vaccine.
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
) before or after being treated with a PD-1/PD-L1
blocking antibody.
PREGNANCY AND LACTATION — Inhibition ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction
Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
, nausea, decreased
appetite, diarrhea, and hematologic toxicity.
PREGNANCY AND LACTATION – Inavolisib ...
Inavolisib (Itovebi – Genentech), an oral kinase
inhibitor, has been approved by the FDA for use in
combination with palbociclib and fulvestrant for
treatment of endocrine-resistant, PIK3CA-mutated,
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer. This is the first
approval for Itovebi; palbociclib and fulvestrant have
been available for years for treatment of HR-positive,
HER2-negative breast cancer.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e186-7 doi:10.58347/tml.2024.1715f | Show Introduction Hide Introduction
Three New Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006 (Issue 1244)
symptoms, particularly withdrawal bleeding, and
decrease the risk of ovulation and pregnancy. One
study ...
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.
Ciclesonide (Omnaris) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
not
affect growth velocity.
4
PREGNANCY — Ciclesonide is rated category C (risk
cannot be ruled out ...
Ciclesonide (Omnaris - Sepracor/Nycomed), a once daily corticosteroid nasal spray, is now available for treatment of seasonal allergic rhinitis (SAR) in adults and children ≥6 years old and for perennial allergic rhinitis (PAR) in those ≥12 years old. An orally inhaled formulation of ciclesonide (Alvesco) was recently approved by the FDA for maintenance treatment of asthma, and will be reviewed in a future issue of The Medical Letter
Oritavancin (Orbactiv) for Skin and Skin Structure Infections
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
of oritavancin and dalbavancin appear
to be similar.
PREGNANCY – Oritavancin is classified as category C ...
The FDA has approved oritavancin (Orbactiv – The
Medicines Company), a long-acting lipoglycopeptide
antibiotic given as a single intravenous (IV) dose, for
treatment of acute bacterial skin and skin structure
infections caused by susceptible gram-positive
bacteria in adults. It is the third lipoglycopeptide
antibiotic to be marketed in the US; telavancin (Vibativ)
and dalbavancin (Dalvance) were approved earlier.
Olodaterol (Striverdi Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015 (Issue 1459)
; there is no
evidence to date that patients with COPD are at risk.
PREGNANCY — Olodaterol is classified as category C ...
Olodaterol (Striverdi Respimat – Boehringer Ingelheim),
a new inhaled long-acting beta2-agonist, has been
approved by the FDA for once-daily maintenance
treatment of airflow obstruction in patients with
chronic obstructive pulmonary disease (COPD). It is
not approved for treatment of acute exacerbations of
COPD or for treatment of asthma. Olodaterol is the third
long-acting beta2-agonist to be approved by the FDA
for once-daily use; indacaterol (Arcapta Neohaler),
which is available as a single agent, and vilanterol,
which is available only in fixed-dose combinations
with the...
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
risk of death compared to placebo.10
PREGNANCY — Stiolto Respimat is classified as
category C (fetal ...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of...
Genvoya - A New 4-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016 (Issue 1488)
if Genvoya
is discontinued.
PREGNANCY — Genvoya is classified as category B
(no evidence of risk ...
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first
approval for tenofovir alafenamide (TAF), a tenofovir
prodrug. Stribild, a fixed-dose combination of
elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate (TDF), was approved in 2012.